MTOR and neoplasm: Furthermore, while verifying the related mechanism, we found a decrease in the protein level of Rictor in the pharmacological-VC-supplemented tumor samples (Fig 5P), indicating the necessity of GSK3-FBXW7-induced Rictor degradation in the pharmacological-VC-dependent mTOR inactivation.